
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Enlivex Therapeutics Ltd (ENLV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ENLV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $10
1 Year Target Price $10
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.72% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.62M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 2 | Beta 0.74 | 52 Weeks Range 0.81 - 1.76 | Updated Date 06/30/2025 |
52 Weeks Range 0.81 - 1.76 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.66 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.24% | Return on Equity (TTM) -60.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7617924 | Price to Sales(TTM) - |
Enterprise Value 7617924 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.49 | Shares Outstanding 23849900 | Shares Floating 20949067 |
Shares Outstanding 23849900 | Shares Floating 20949067 | ||
Percent Insiders 4.61 | Percent Institutions 13.43 |
Analyst Ratings
Rating 2 | Target Price 10 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Enlivex Therapeutics Ltd

Company Overview
History and Background
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company. Founded in 2005, it focuses on developing Allocetra, a cell-based therapy, for the treatment of life-threatening inflammatory and immune conditions.
Core Business Areas
- Immunotherapy Development: Focuses on research, development, and commercialization of Allocetra, its lead product candidate.
Leadership and Structure
Dr. Oren Hershkovitz serves as CEO. The company has a board of directors overseeing strategic direction and management.
Top Products and Market Share
Key Offerings
- Allocetra: Allocetra is an investigational cell-based immunotherapy aimed at treating organ dysfunction and inflammatory conditions associated with various diseases, including sepsis and COVID-19. Given its developmental stage, precise market share and revenue figures are unavailable. Competition includes broad spectrum antibiotics and supportive care for sepsis, and antivirals, anti-inflammatory drugs, and ventilation for COVID-19-related organ dysfunction. Direct competitors are other companies developing advanced therapies for sepsis or severe inflammatory conditions, such as Cytokine Modulators.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing substantial growth driven by advancements in cell therapies and increasing prevalence of immune-related diseases. High unmet need and the potential for breakthrough therapies are key drivers.
Positioning
Enlivex is positioned as an innovator in the cell-based immunotherapy space, specifically targeting severe inflammatory conditions with Allocetra. Its competitive advantage lies in its unique mechanism of action and potential to address unmet needs.
Total Addressable Market (TAM)
The global sepsis therapeutics market is projected to reach billions of USD. Enlivex's position depends on successful clinical trials and regulatory approvals for Allocetra, but the TAM is potentially very large for effective treatments.
Upturn SWOT Analysis
Strengths
- Novel cell-based immunotherapy approach
- Focus on addressing unmet medical needs
- Experienced management team
- Positive preclinical and early clinical trial data (limited data)
Weaknesses
- Reliance on single product candidate (Allocetra)
- Clinical trial risks and regulatory hurdles
- Limited financial resources compared to larger pharmaceutical companies
- No products are currently approved or generating revenue.
Opportunities
- Expansion of Allocetra's application to other inflammatory conditions
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approvals
- Increased awareness and adoption of cell-based immunotherapies
Threats
- Failure of clinical trials
- Regulatory setbacks
- Competition from established therapies and new entrants
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- BMY
- REGN
Competitive Landscape
Enlivex is a smaller player competing with larger, established pharmaceutical companies. Its advantage lies in its novel technology, but it faces significant challenges in terms of resources and market access. The larger pharmaceutical companies are also developing medications to combat diseases.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing Allocetra through clinical trials and securing funding.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals for Allocetra, as well as potential partnerships or acquisitions. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing clinical trials for sepsis and COVID-19-related organ dysfunction and efforts to secure additional funding.
Summary
Enlivex Therapeutics is a high-risk, high-reward clinical-stage company focused on developing Allocetra. Its success hinges on the outcome of clinical trials and regulatory approvals. The company has a novel approach but faces challenges in funding and competition. Positive results from ongoing trials could significantly improve its market position, while setbacks could have a negative impact. The company does not have any revenue as of the moment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enlivex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-12-12 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.enlivex.com |
Full time employees - | Website https://www.enlivex.com |
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.